Nicolas Tournier1, Martin Bauer2, Verena Pichler3, Lukas Nics3, Eva-Maria Klebermass3, Karsten Bamminger4,3, Peter Matzneller4, Maria Weber4, Rudolf Karch5, Fabien Caillé1, Sylvain Auvity1, Solène Marie1, Walter Jäger6, Wolfgang Wadsak3,7, Marcus Hacker3, Markus Zeitlinger4, Oliver Langer4,3,8. 1. UMR 1023 IMIV, Service Hospitalier Frédéric Joliot, CEA, Inserm, Université Paris Sud, CNRS, Université Paris-Saclay, Orsay, France. 2. Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria martin.m.bauer@meduniwien.ac.at. 3. Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria. 4. Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. 5. Centre for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria. 6. Department of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna, Austria. 7. Center for Biomarker Research in Medicine-CBmed GmbH, Graz, Austria; and. 8. Biomedical Systems, Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
Abstract
PET with avid substrates of P-glycoprotein (ABCB1) provided evidence of the role of this efflux transporter in effectively restricting the brain penetration of its substrates across the human blood-brain barrier (BBB). This may not reflect the situation for weak ABCB1 substrates including several antidepressants, antiepileptic drugs, and neuroleptics, which exert central nervous system effects despite being transported by ABCB1. We performed PET with the weak ABCB1 substrate 11C-metoclopramide in humans to elucidate the impact of ABCB1 function on its brain kinetics. Methods: Ten healthy male subjects underwent 2 consecutive 11C-metoclopramide PET scans without and with ABCB1 inhibition using cyclosporine A (CsA). Pharmacokinetic modeling was performed to estimate the total volume of distribution (VT) and the influx (K1) and efflux (k2) rate constants between plasma and selected brain regions. Furthermore, 11C-metoclopramide washout from the brain was estimated by determining the elimination slope (kE,brain) of the brain time-activity curves. Results: In baseline scans, 11C-metoclopramide showed appreciable brain distribution (VT = 2.11 ± 0.33 mL/cm3). During CsA infusion, whole-brain gray matter VT and K1 were increased by 29% ± 17% and 9% ± 12%, respectively. K2 was decreased by 15% ± 5%, consistent with a decrease in kE,brain (-32% ± 18%). The impact of CsA on outcome parameters was significant and similar across brain regions except for the pituitary gland, which is not protected by the BBB. Conclusion: Our results show for the first time that ABCB1 does not solely account for the "barrier" property of the BBB but also acts as a detoxifying system to limit the overall brain exposure to its substrates at the human blood-brain interface.
PET with avid substrates of P-glycoprotein (ABCB1) provided evidence of the role of this efflux transporter in effectively restricting the brain penetration of its substrates across the human blood-brain barrier (BBB). This may not reflect the situation for weak ABCB1 substrates including several antidepressants, antiepileptic drugs, and neuroleptics, which exert central nervous system effects despite being transported by ABCB1. We performed PET with the weak ABCB1 substrate 11C-metoclopramide in humans to elucidate the impact of ABCB1 function on its brain kinetics. Methods: Ten healthy male subjects underwent 2 consecutive 11C-metoclopramide PET scans without and with ABCB1 inhibition using cyclosporine A (CsA). Pharmacokinetic modeling was performed to estimate the total volume of distribution (VT) and the influx (K1) and efflux (k2) rate constants between plasma and selected brain regions. Furthermore, 11C-metoclopramide washout from the brain was estimated by determining the elimination slope (kE,brain) of the brain time-activity curves. Results: In baseline scans, 11C-metoclopramide showed appreciable brain distribution (VT = 2.11 ± 0.33 mL/cm3). During CsA infusion, whole-brain gray matter VT and K1 were increased by 29% ± 17% and 9% ± 12%, respectively. K2 was decreased by 15% ± 5%, consistent with a decrease in kE,brain (-32% ± 18%). The impact of CsA on outcome parameters was significant and similar across brain regions except for the pituitary gland, which is not protected by the BBB. Conclusion: Our results show for the first time that ABCB1 does not solely account for the "barrier" property of the BBB but also acts as a detoxifying system to limit the overall brain exposure to its substrates at the human blood-brain interface.
Authors: Angela Doran; R Scott Obach; Bill J Smith; Natilie A Hosea; Stacey Becker; Ernesto Callegari; Cuiping Chen; Xi Chen; Edna Choo; Julie Cianfrogna; Loretta M Cox; John P Gibbs; Megan A Gibbs; Heather Hatch; Cornelis E C A Hop; Ilana N Kasman; Jennifer Laperle; Jianhua Liu; Xingrong Liu; Michael Logman; Debra Maclin; Frank M Nedza; Frederick Nelson; Emily Olson; Sandhya Rahematpura; David Raunig; Sabrinia Rogers; Kari Schmidt; Douglas K Spracklin; Mark Szewc; Matthew Troutman; Elaine Tseng; Meihua Tu; Jeffrey W Van Deusen; Karthik Venkatakrishnan; Gary Walens; Ellen Q Wang; Diane Wong; Adam S Yasgar; Chenghong Zhang Journal: Drug Metab Dispos Date: 2004-10-22 Impact factor: 3.922
Authors: Gert Luurtsema; Carla F M Molthoff; Robert C Schuit; Albert D Windhorst; Adriaan A Lammertsma; Eric J F Franssen Journal: Nucl Med Biol Date: 2005-01 Impact factor: 2.408
Authors: Bo Feng; Jessica B Mills; Ralph E Davidson; Rouchelle J Mireles; John S Janiszewski; Matthew D Troutman; Sonia M de Morais Journal: Drug Metab Dispos Date: 2007-10-25 Impact factor: 3.922
Authors: Alexander Hammers; Richard Allom; Matthias J Koepp; Samantha L Free; Ralph Myers; Louis Lemieux; Tejal N Mitchell; David J Brooks; John S Duncan Journal: Hum Brain Mapp Date: 2003-08 Impact factor: 5.038
Authors: Viktoria Zoufal; Severin Mairinger; Mirjam Brackhan; Markus Krohn; Thomas Filip; Michael Sauberer; Johann Stanek; Thomas Wanek; Nicolas Tournier; Martin Bauer; Jens Pahnke; Oliver Langer Journal: J Nucl Med Date: 2019-12-05 Impact factor: 11.082
Authors: Martin Bauer; Karsten Bamminger; Verena Pichler; Maria Weber; Simon Binder; Alexandra Maier-Salamon; Ammar Tahir; Walter Jäger; Helmuth Haslacher; Nicolas Tournier; Marcus Hacker; Markus Zeitlinger; Oliver Langer Journal: Clin Pharmacol Ther Date: 2020-10-14 Impact factor: 6.903